8-K: Viridian Therapeutics Holds Annual Meeting, Elects Directors
Annual Meeting Results
Viridian Therapeutics, Inc. announced the results of its 2026 Annual Meeting of Stockholders, including the election of directors and approval of key proposals.
Summary
- Viridian Therapeutics, Inc. held its 2026 Annual Meeting of Stockholders on June 2, 2026.
- Stockholders of record as of April 7, 2026, were eligible to vote.
- A total of 103,071,889 shares of common stock were outstanding.
- Two Class II director nominees, Tomas Kiselak and Jennifer K. Moses, were elected to serve until the 2029 Annual Meeting.
- KPMG LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
- The compensation of named executive officers was approved on an advisory basis.
- Stockholders approved, on an advisory basis, holding an advisory vote on executive compensation annually.
Sentiment
Score: 6
Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, reflecting routine corporate governance and operational stability without significant new strategic information or financial performance indicators.
Positives
- Directors Tomas Kiselak and Jennifer K. Moses were elected with significant support.
- KPMG LLP was ratified as the independent auditor with overwhelming approval.
- The compensation of named executive officers received advisory approval.
- The frequency of advisory votes on executive compensation was overwhelmingly set to annually.
Future Outlook
The company will conduct a non-binding advisory vote on the compensation of its named executive officers every year.
Industry Context
StockSavvy.ai notes that the routine approval of director nominees, auditor ratification, and executive compensation at an annual meeting is standard practice for publicly traded companies and indicates stable corporate governance.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Director Election | Election of two Class II director nominees to serve until the 2029 Annual Meeting of Stockholders. | 2026-06-02 | Maintains board continuity and governance structure. |
| Auditor Ratification | Ratification of the selection of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026. | 2026-06-02 | Ensures continued independent financial oversight. |
| Executive Compensation Vote Frequency | Approval, on an advisory basis, of the frequency of holding an advisory vote on the compensation of the Company's named executive officers. | 2026-06-02 | Establishes an annual advisory vote on executive compensation. |
Stakeholder Impact
- Shareholders: Confirmation of board leadership and auditor provides stability. Annual advisory vote on compensation allows continued shareholder input.
Next Steps
- The company will conduct an advisory vote on executive compensation annually.
- Elected directors Tomas Kiselak and Jennifer K. Moses will serve their terms.
Key Dates
| Date | Description |
|---|---|
| 2026-04-07 | Record Date for determining stockholders entitled to vote at the Annual Meeting. |
| 2026-06-02 | Date of the 2026 Annual Meeting of Stockholders. |
| 2026-06-03 | Date of the report signing. |
| 2026-12-31 | Fiscal year end for which KPMG LLP is the independent registered public accounting firm. |
| 2029-01-01 | Term end for elected Class II directors (estimated). |
Keywords
Viridian Therapeutics, Annual Meeting, Stockholders, Director Election, KPMG LLP, Executive Compensation, Corporate Governance, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.